BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17699331)

  • 1. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations.
    Huugen D; Tervaert JW; Heeringa P
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1100-7. PubMed ID: 17699331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [ANCA-associated vasculitis (Wegener's granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). 3. Therapeutic procedure].
    Reinhold-Keller E; Tatsis E; Gross WL
    Z Rheumatol; 1995; 54(5):303-9. PubMed ID: 8578886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases.
    Feldmann M; Pusey CD
    J Am Soc Nephrol; 2006 May; 17(5):1243-52. PubMed ID: 16624928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wegener's granulomatosis.
    Lamprecht P; Gross WL
    Herz; 2004 Feb; 29(1):47-56. PubMed ID: 14968341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting B lymphocytes as therapy for ANCA-associated vasculitis.
    Golbin JM; Specks U
    Rheum Dis Clin North Am; 2007 Nov; 33(4):741-54, v. PubMed ID: 18037114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Churg-Strauss syndrome.
    Keogh KA; Specks U
    Semin Respir Crit Care Med; 2006 Apr; 27(2):148-57. PubMed ID: 16612766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.
    Mukhtyar C; Luqmani R
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv31-6. PubMed ID: 16239383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis.
    Kallenberg CG
    Curr Opin Rheumatol; 2007 Jan; 19(1):17-24. PubMed ID: 17143091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of ANCA-associated systemic vasculitis.
    Belmont HM
    Bull NYU Hosp Jt Dis; 2006; 64(1-2):60-6. PubMed ID: 17121492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An index for renal outcome in ANCA-associated glomerulonephritis.
    Vergunst CE; van Gurp E; Hagen EC; van Houwelingen HC; Hauer HA; Noël LH; Waldherr R; Ferrario F; van der Woude FJ; Bruijn JA; Bajema IM;
    Am J Kidney Dis; 2003 Mar; 41(3):532-8. PubMed ID: 12612975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity.
    Vizjak A; Rott T; Koselj-Kajtna M; Rozman B; Kaplan-Pavlovcic S; Ferluga D
    Am J Kidney Dis; 2003 Mar; 41(3):539-49. PubMed ID: 12612976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides.
    Kallenberg CG; Heeringa P; Stegeman CA
    Nat Clin Pract Rheumatol; 2006 Dec; 2(12):661-70. PubMed ID: 17133251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of ANCA associated systemic necrotizing vasculitides].
    Guillevin L
    Bull Acad Natl Med; 2008; 192(6):1175-87; discussion 1188. PubMed ID: 19235481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies.
    Choi HK; Liu S; Merkel PA; Colditz GA; Niles JL
    J Rheumatol; 2001 Jul; 28(7):1584-90. PubMed ID: 11469466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of PR3-ANCA associated vasculitis.
    Kallenberg CG
    J Autoimmun; 2008; 30(1-2):29-36. PubMed ID: 18162369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ANCA-associated forms of vasculitis].
    Helmchen U; Kneissler U; Prall F
    Verh Dtsch Ges Pathol; 1996; 80():38-45. PubMed ID: 9065053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis.
    Reynolds WF; Stegeman CA; Tervaert JW
    Clin Immunol; 2002 May; 103(2):154-60. PubMed ID: 12027420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunopathology of ANCA-associated vasculitis.
    Csernok E; Müller A; Gross WL
    Intern Med; 1999 Oct; 38(10):759-65. PubMed ID: 10526937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Necrotizing vasculitis--a 2009 update.
    Sharaf PH; Yazici Y
    Bull NYU Hosp Jt Dis; 2009; 67(3):303-5. PubMed ID: 19852754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.